Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label perioperative SHR-A2102 combination therapy in resectable non-small cell lung cancer
CTR20254159Phase 2Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SHR-A2102 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Suzhou Shengdiya Biopharmaceuticals. Primary endpoints: Pathological complete response rate, 18-month event-free survival rate and 1 more. Started Nov 2025; status: active.
02
Drugs
SHR-A2102
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20254159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254159.